Theravance Biopharma (TBPH) Will Present VIBATIV Data at Upcoming Conference; Includes TOUR Study Numbers
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- Wall St slips as higher yields offset upbeat corporate earnings
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Boeing reports first revenue drop in 7 quarters as deliveries decline
- Oil prices slip as U.S. business activity cools, concerns over Middle East ease
- Yen on the brink, but Tesla pulls back
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Hasbro (HAS) brand strength sees earnings top expectations
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV(R) (telavancin), Including Ongoing TOUR(TM) Observational Patient Registry, at IDWeek 2016
October 18, 2016 8:05 AM EDTDUBLIN, IRELAND -- (Marketwired) -- 10/18/16 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that data from new studies of VIBATIV (telavancin) will be presented at IDWeek" 2016, being held in New Orleans, LA on October 26 - 30, 2016. Researchers will present interim data from the first 200 patients enrolled in the Company's ongoing Telavancin Observational Use Registry (TOUR") study, highlighting clinical response rates and prescribing patterns for VIBATIV. TOUR is designed to assess how the antibiotic is being used by healthcare practitioners to treat patients in real-world clinical settings.
Additional presentations... More
